Heartflow (NASDAQ:HTFL) Insider Campbell Rogers Sells 23,933 Shares of Company Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 23,933 shares of the business’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total value of $1,316,554.33. Following the completion of the transaction, the insider owned 73,453 shares of the company’s stock, valued at $4,040,649.53. This trade represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total value of $987,052.30.
• On Monday, August 17th, Campbell Rogers sold 9,219 shares of Heartflow stock. The stock was sold at an average price of $41.23, for a total value of $380,099.37.

Heartflow Price Performance

Shares of NASDAQ:HTFL traded up $0.30 during midday trading on Monday, reaching $57.01. The company’s stock had a trading volume of 1,058,656 shares, compared to its average volume of 1,655,511. The business has a 50 day moving average price of $49.38 and a 200 day moving average price of $33.51. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $57.74.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The company had revenue of $64.08 million during the quarter. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Equities research analysts forecast that Heartflow, Inc. will post -0.75 EPS for the current year.

Analyst Upgrades and Downgrades

HTFL has been the subject of a number of research analyst reports. Wells Fargo & Company upped their price objective on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. JPMorgan Chase & Co. lifted their target price on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Morgan Stanley upped their price target on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Finally, Robert W. Baird set a $45.00 price objective on Heartflow in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Heartflow presently has an average rating of “Moderate Buy” and a consensus price target of $48.62.

Institutional Trading of Heartflow

A number of institutional investors have recently added to or reduced their stakes in HTFL. Sterling Capital Management LLC grew its position in shares of Heartflow by 797.9% in the 3rd quarter. Sterling Capital Management LLC now owns 2,532 shares of the company’s stock worth $126,000 after acquiring an additional 2,250 shares in the last quarter. Crescent Grove Advisors LLC acquired a new position in Heartflow in the third quarter worth $249,000. IFP Advisors Inc increased its stake in Heartflow by 844.7% during the third quarter. IFP Advisors Inc now owns 803 shares of the company’s stock valued at $40,000 after purchasing an additional 718 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in Heartflow during the third quarter valued at $1,020,000. Finally, Avior Wealth Management LLC raised its holdings in shares of Heartflow by 16.1% during the third quarter. Avior Wealth Management LLC now owns 14,553 shares of the company’s stock worth $724,000 after purchasing an additional 2,023 shares during the period.

About Heartflow

Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries and provide noninvasive assessments of blood flow and disease.

The company’s products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.